Photo by satheeshsankaran from unsplash
Friedreich ataxia (FRDA) is a rare disorder with progressive neurodegeneration and cardiomyopathy. Luvadaxistat (also known as TAK‐831; NBI‐1065844), an inhibitor of the enzyme d‐amino acid oxidase, has demonstrated beneficial effects… Click to show full abstract
Friedreich ataxia (FRDA) is a rare disorder with progressive neurodegeneration and cardiomyopathy. Luvadaxistat (also known as TAK‐831; NBI‐1065844), an inhibitor of the enzyme d‐amino acid oxidase, has demonstrated beneficial effects in preclinical models relevant to FRDA. This phase 2, randomized, double‐blind, placebo‐controlled, parallel‐arm study evaluated the efficacy and safety of oral luvadaxistat in adults with FRDA.
Keywords:
randomized double;
luvadaxistat adults;
friedreich ataxia;
study;
double blind
Journal Title: Annals of Clinical and Translational Neurology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Annals of Clinical and Translational Neurology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!